osbpl7in1

GLP-1(7-36), amide (MKC 253) is a peptide hormone released from intestinal L-cells upon nutrient consumption. It binds the GLP-1 receptor in the pancreas and displays various antidiabetic effects by potentiating glucose-induced secretion of insulin from pancreatic β-cells, increasing insulin expression.

Hemokinin 1 (human) acetate is an endogenous substance P homolog that is a selective agonist at the tachykinin NK1 receptor (IC50 values are 1.8, 370 and 480 nM for NK1, NK3 and NK2 receptors respectively). Has proliferative and antiapoptotic actions on B

Substance P (1-7) 2TFA(68060-49-1(free base)) is the major bioactive metabolite formed after proteolytic degradation of the tachykinin substance P (SP),with anti-inflammatory, anti-nociceptive and anti-hyperalgesic effects

Nociceptin (1-7) acetate is a potent agonist of opioid receptor-like 1 (ORL1) receptor. Nociceptin (1-7) combines with nociceptin reduces hyperalgesia and has antinociceptive activity.

Angiotensin 1/2 (5-7) acetate is a peptide with the sequence H2N-Ile-His-Pro-OH. Angiotensin is an oligopeptide and is a hormone and a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It

Orphanin FQ(1-11) acetate(178249-41-7 free base) is a peptide fragment containing amino acids 1-11 of Nociceptin. Orphanin FQ(1-11) acetate(178249-41-7 free base) is a potent agonist of the ORL1/KOR-3 receptor (Ki = 55 nM) and displays no affinity for opioid receptors, including μ, δ, κ1 and κ3 receptors (Ki >1000 nM). Orphanin FQ(1-11) acetate(178249-41-7 free base) displays analgesic properties in CD-1 mice.

Substance P(1-7) (Substance P 1-7) is the major bioactive metabolite formed after proteolytic degradation of the tachykinin substance P (SP),with anti-inflammatory, anti-nociceptive and anti-hyperalgesic effects

Acetyl-(D-Phe2,Lys15,Arg16,Leu27)-VIP(1-7)-GRF(8-27) is a selective antagonist [1] for the vasoactive intestinal peptide 1 (VIP 1) receptor.

Bradykinin (1-7), an amino-truncated peptide derived from Bradykinin, is a metabolite formed through enzymatic cleavage by endopeptidase.

α-Bag Cell Peptide (1-7) is an amino-terminal fragment of the α-bag cell peptide that possesses the ability to inhibit neurons in the left upper quadrant (LUQ) and prevent the depolarization of the bag cells [1].

[K15,R16,L27]VIP(1-7)/GRF(8-27), a selective agonist for the VIP 1 receptor, demonstrates binding IC 50 values of 2 nM for the human VIP 1, 1 nM for the rat VIP 1, and 30,000 nM for the rat VIP 2 receptors, respectively [1]. VIP stands for VASOACTIVE Intestinal Polypeptide.

GLP-1 (7-37) is a truncated, bioactive form of GLP-1 that is the product of proglucagon processing in intestinal endocrine L cells.

[K15,R16,L27]VIP(1-7)/GRF(8-27) (acetate) is an acetate salt form of the peptide [K15,R16,L27]VIP(1-7)/GRF(8-27). This compound acts as a selective agonist for the VIP 1 receptor, displaying IC50 values of 2 nM for human VIP 1, 1 nM for rat VIP 1, and 30,000 nM for rat VIP 2 receptors [1]. The peptide's acronym, VIP, stands for Vasoactive Intestinal Polypeptide.

Substance P(1-7) TFA, a fragment of the neuropeptide substance P (SP), induces depressor and bradycardic effects upon application to the nucleus tractus solitarius [1].

Glp-1(7-37) acetate is an intestinal insulin hormone that enhances glucose-induced insulin secretion.

Angiotensin 1-7 (Ang-(1-7)) acetate, an endogenous heptapeptide from the renin-angiotensin system (RAS), exhibits cardioprotective effects through its anti-inflammatory and anti-fibrotic activities in cardiac cells. It effectively inhibits purified canine ACE activity (IC 50 =0.65 μM) and serves as a local synergistic modulator of kinin-induced vasodilation by hindering ACE and facilitating nitric oxide release. Additionally, this compound prevents Ang II-induced proliferation and hypertrophy in smooth muscle cells, alongside demonstrating antiangiogenic and growth-inhibitory effects on the endothelium [1] [2] [3].

GLP-1(7-36), amide TFA is a prominent intestinal hormone known to stimulate glucose-induced insulin secretion from β cells[1].

Angiotensin (1-7) (ASP-ARG-VAL-TYR-ILE-HIS-PRO) is a synthetic heptapeptide identical to endogenous angiotensin-(1-7) , inhibits purified canine ACE activity (IC50=0.65 μM) with vasodilator and antiproliferative activities.

Glucagon-Like Peptide 1 (GLP-1) (7-36)-Lys (Biotin), amide, human, is a human GLP-1 (7-36) amide that has been biotinylated at the C-terminal.

(Ser8)-GLP-1 (7-36) amide, human is a glucagon-like peptide-1 amide originating from glucagonogen, itself a cleavage product of the GLP-1 (1-36) amide peptide. This entero-insulinotropic hormone facilitates glucose-dependent insulin secretion from pancreatic β-cells and influences gastrointestinal motility and secretion [1].

GLP-1(7-36) Acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

Human glucagon-like peptide-1-(7-36)-Lys(Biotin) amide, a biotin-labeled variant of glucagon-like peptide-1-(7-36), is a gastrointestinal peptide recognized for its antidiabetogenic properties, including the ability to enhance insulin secretion [1] [2].

Cecropin A (1-7)-Melittin A (2-9) is an antimicrobial peptide that exhibits broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative aerobic bacteria, in addition to antimalarial properties. Notably, it does not possess the adverse hemolytic effects commonly associated with bee venom peptides [1].

Bioactive metabolite of nociceptin, antagonist of nociceptin-induced hyperalgesia

Substance P (1-7)(TFA) is a fragment of the neuropeptide, substance P (SP).

Nociceptin (1-7) TFA, the N-terminal bioactive fragment of nociceptin, serves as a potent ORL 1 (NOP) receptor agonist, exhibiting antinociceptive properties. Its combination with nociceptin effectively reduces hyperalgesia in vivo [1].